Beranda › Limfoma Burkitt › Massachusetts › Worcester
Uji klinis Limfoma Burkitt di Worcester, MA
3 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Worcester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- UMass Memorial Medical Center - University Campus, Worcester
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- UMass Memorial Medical Center - University Campus, Worcester
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- UMass Memorial Medical Center - University Campus, Worcester
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Boston, MA10 studi
- Durham, NC10 studi
- Aurora, CO10 studi
- Los Angeles, CA10 studi
Studi lain di Worcester
- Kanker Paru Non-Sel Kecil14 studi
- Kanker Paru11 studi
- Kanker (semua jenis)7 studi
- Kanker Payudara6 studi
- Skizofrenia5 studi
- Kanker Metastatik5 studi
- Kanker Prostat5 studi
- Kanker Ovarium5 studi
- Gangguan Depresi Mayor5 studi
- Depresi5 studi
- Leukemia Mieloid Akut5 studi
- Karsinoma Urotelial (Sel Transisional)4 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.